抗体介导肾移植排斥中细胞毒性CD8+和CD4+ T细胞的移植物内克隆扩增
该研究通过四个独立队列(192例 bulk 转录组、16例单细胞RNA/TCR测序、18例和75例多重免疫染色)分析肾移植活检,发现AMR/MVI样本中CD8+ T细胞显著富集,且克隆扩增主要见于CD8+ Tem/Temra、CD4+细胞毒性T细胞和CD8+ HLA-DR+CD27+ T细胞,4例AMR活检中克隆扩增T细胞比例最高,提示AMR与TCMR的传统二分法需要重新审视。
要点
- AMR/MVI活检中CD8+ T细胞显著富集,程度与 borderline TCMR 相当。
- 克隆扩增主要见于细胞毒性CD8+和CD4+ T细胞亚群,CD4+ Naïve/Tcm 几乎不扩增。
- 早期AMR伴预存DSA且无TCMR组织学诊断的活检中克隆扩增T细胞比例最高。
核心结论
- 早期AMR活检中存在克隆扩增的CD4+和CD8+细胞毒性T细胞,即使无TCMR组织学诊断。
- AMR与TCMR的传统二分法可能需要重新考虑。
研究设计与样本
- 分析四个独立队列的肾移植活检数据集:192例 bulk 转录组、16例单细胞RNA/TCR测序、18例和75例多重免疫染色。
主要发现
- Bulk转录组反卷积显示33例AMR/MVI样本较139例无排斥样本CD8+ T细胞显著富集,与20例(borderline)TCMR水平相当。
- scRNA-Seq无监督聚类识别五个主要T细胞簇,克隆扩增主要见于CD8+ Tem/Temra、CD4+细胞毒性T细胞和CD8+ HLA-DR+CD27+ T细胞。
- CD4+ Naïve/Tcm簇大多未扩增;另一CD8+簇以早期活化标志(CD69+、FOS+、JUN+)和中度克隆性为特征。
- 4例AMR活检中克隆扩增T细胞比例最高,其中3例为预存DSA且无TCMR组织学诊断的早期AMR。
- 扩增T细胞比例和不同扩增克隆数与PIRCHE-II评分相关;空间蛋白质组学证实AMR/MVI活检血管内和肾小球区域T细胞富集。
临床怎么用
- 对早期AMR伴预存DSA但无TCMR组织学诊断的病例,应关注移植物内细胞毒性T细胞克隆扩增。
- PIRCHE-II评分可能与T细胞克隆扩增程度相关,或可辅助评估排斥的细胞机制复杂性。
局限性
- 单细胞RNA/TCR测序样本量较小(16例,其中AMR活检4例)。
- 原文未报告部分分析的具体统计阈值和P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The traditional dichotomy between antibody-mediated rejection (AMR) and T cell-mediated rejection (TCMR) after kidney transplantation is increasingly challenged. While T cell populations and their clonal expansion have been demonstrated in TCMR, the involvement and clonality of T cells remain unexplored in AMR. METHODS: Kidney transplant biopsy datasets from four independent cohorts (192 cases bulk transcriptomics, 16 cases of single-cell RNA/TCR sequencing, along with 18 and 75 cases of multiplex immunostaining) were analyzed to characterize CD4+ and CD8+ T cell enrichment, clonal expansion and spatial organization in AMR and microvascular inflammation (MVI). RESULTS: Deconvolution of bulk transcriptomes showed a significant enrichment of CD8+ T cells in 33 AMR/MVI samples versus 139 no rejection, with comparable levels between AMR/MVI and 20 (borderline) TCMR cases. Unsupervised clustering of scRNA-Seq data identified five major T cell clusters. Clonal expansion was mostly present in CD8+ Tem/Temra cells, CD4+ cytotoxic T cells and CD8+ HLA-DR+ CD27+ T cells. The CD4+ Naïve/Tcm cluster was mostly not expanded. The last CD8+ cluster was characterized by early activation markers (CD69+, FOS+, JUN+) and intermediate clonality. The four AMR biopsies had the highest proportion of clonally expanded T cells, most notably in early AMR cases in patients with pre-existing donor-specific antibodies without histological diagnosis of TCMR in three cases. Both the fraction of expanded T cells and the number of distinct expanded clones correlated with the PIRCHE-II score, which estimates the number of donor HLA-derived epitopes presented by the recipient's HLA molecules. Finally, spatial proteomics confirmed the T-cell enrichment in the intravascular and glomerular compartments of AMR/MVI biopsies. CONCLUSIONS: We demonstrated the presence of clonally expanded CD4+ and CD8+ cytotoxic T cells in early AMR biopsies with pre-existing donor-specific antibodies without histological diagnosis of TCMR. These findings highlight a level of complexity in the cellular mechanisms of rejection not currently captured by routine histology, suggesting that the dichotomy between AMR and TCMR needs reconsideration.
引用
- Vaulet T, Lamarthée B, Callemeyn J, et al. Intragraft clonal expansion of cytotoxic CD8+ and CD4+ T cells in antibody-mediated kidney transplant rejection. Kidney Int. 2026. PMID: 42034201. doi:10.1016/j.kint.2026.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。